BACKGROUND Immunotherapy,specifically the use of checkpoint inhibitors such as pembrolizumab,has become an important tool in personalized cancer therapy.These inhibitors target proteins on T-cells that regulate the im...BACKGROUND Immunotherapy,specifically the use of checkpoint inhibitors such as pembrolizumab,has become an important tool in personalized cancer therapy.These inhibitors target proteins on T-cells that regulate the immune response against tumor cells.Pembrolizumab,which targets the programmed cell death 1 receptor on T-cells,has been approved for the treatment of metastatic melanoma and nonsmall cell lung cancer.However,it can also lead to immune-related side effects,including pneumonitis,colitis,thyroid abnormalities,and rare cases of type 1 diabetes.CASE SUMMARY The case presented involves an adult patient in 30s with breast cancer who developed hyperglycemia after receiving pembrolizumab treatment.The patient was diagnosed with diabetic ketoacidosis and further investigations were performed to evaluate for new-onset type 1 diabetes.The patient had a history of hypothyroidism and a family history of breast cancer.Treatment for diabetic ketoacidosis was initiated,and the patient was discharged for close follow-up with an endocrinologist.CONCLUSION This literature review highlights the occurrence of diabetic ketoacidosis and newonset type 1 diabetes in patients receiving pembrolizumab treatment for different types of cancer.Overall,the article emphasizes the therapeutic benefits of immunotherapy in cancer treatment,particularly pembrolizumab,while also highlighting the potential side effect of immune-related diabetes that can occur in a small percentage of patients.Here we present a case where pembrolizumab lead to development of diabetes after a few cycles highlighting one of the rare yet a serious toxicity of the drug.展开更多
文摘BACKGROUND Immunotherapy,specifically the use of checkpoint inhibitors such as pembrolizumab,has become an important tool in personalized cancer therapy.These inhibitors target proteins on T-cells that regulate the immune response against tumor cells.Pembrolizumab,which targets the programmed cell death 1 receptor on T-cells,has been approved for the treatment of metastatic melanoma and nonsmall cell lung cancer.However,it can also lead to immune-related side effects,including pneumonitis,colitis,thyroid abnormalities,and rare cases of type 1 diabetes.CASE SUMMARY The case presented involves an adult patient in 30s with breast cancer who developed hyperglycemia after receiving pembrolizumab treatment.The patient was diagnosed with diabetic ketoacidosis and further investigations were performed to evaluate for new-onset type 1 diabetes.The patient had a history of hypothyroidism and a family history of breast cancer.Treatment for diabetic ketoacidosis was initiated,and the patient was discharged for close follow-up with an endocrinologist.CONCLUSION This literature review highlights the occurrence of diabetic ketoacidosis and newonset type 1 diabetes in patients receiving pembrolizumab treatment for different types of cancer.Overall,the article emphasizes the therapeutic benefits of immunotherapy in cancer treatment,particularly pembrolizumab,while also highlighting the potential side effect of immune-related diabetes that can occur in a small percentage of patients.Here we present a case where pembrolizumab lead to development of diabetes after a few cycles highlighting one of the rare yet a serious toxicity of the drug.
